1. Introduction {#sec1-1}
===============

It has been increasingly recognized that schizophrenia is associated with impairment in pleasure experience.^\[[@ref1]\]^ Patients with schizophrenia may be impaired in both pleasure experience and emotion expression, which may cause significant disability.^\[[@ref4]\]^ Although negative symptoms and affective flattening are considered core features of schizophrenia, there exists significant heterogeneity in symptom presentation in patients with schizophrenia.

Experience of pleasure could be divided into anticipatory pleasure and consummatory pleasure.^\[[@ref5],[@ref6]\]^ Anticipatory pleasure is linked with motivation and goal-directed behaviour, while consummatory pleasure is related to in-the-moment experience. Many studies have shown that patients with schizophrenia are impaired in anticipatory pleasure, especially abstract anticipatory pleasure, but relatively intact in consummatory pleasure experience.^\[[@ref7],[@ref8]\]^ However, Straus et al reported an opposite pattern in which patients with schizophrenia differed from healthy controls in consummatory pleasure but not anticipatory pleasure.^\[[@ref9]\]^ Gooding et al reported that individuals with high levels of social anhedonia are impaired in both anticipatory and consummatory pleasure.^\[[@ref10]\]^ Based on the two-factor model of the Temporal Experience of Pleasure Scale (TEPS), Chan reported a four-factor Chinese version of the TEPS that comprised abstract and contextual domains under anticipatory and consummatory pleasure.^\[[@ref11]\]^ Li et al further replicated this four-factor model of the TEPS in patients in different stages of schizophrenia in the Chinese setting.^\[[@ref12]\]^ They also found that patients with first episode and chronic schizophrenia and people with schizotypal features reported lower levels of abstract anticipatory pleasure, but not all of them reported lower levels of contextual anticipatory pleasure compared with healthy controls.

Patients with schizophrenia may not only be impaired in pleasure experience, but also in expressing emotion. A general impairment in emotion expression has been reported in schizophrenia patients.^\[[@ref13]\]^ Previous studies have shown that patients with schizophrenia are unable to recognize and describe their feelings (alexithymia), are less expressive (both facially and vocally) than individuals without this disorder,^\[[@ref14]\]^ and have diminished ability to outwardly express emotion.^\[[@ref15]\]^ Shi et al showed that individuals with negative schizotypal personality disorder features exhibited deficits in self-reported emotion expression, but little is known about patients with schizophrenia.^\[[@ref16]\]^

Previous studies have shown that emotion impairment is correlated with clinical symptoms.^\[[@ref7],[@ref17]\]^ Negative symptoms are a core feature of schizophrenia.^\[[@ref18]\]^ Kring and Brach conceptualized the structure of negative symptoms as a two-factor model, namely diminished motivation and pleasure (anhedonia) and diminished verbal and non-verbal expression and communication (flat affect and poor speech).^\[[@ref4]\]^ Anhedonia represents a deficit in the "experience" of emotion, and flat affect reflects a deficit in the "expression" of emotion.^\[[@ref19]\]^ Some attempts have been made to examine the correlations between emotion impairments and negative symptoms. Kohler et al demonstrated that emotion recognition deficits were significantly correlated with alogia.^\[[@ref20]\]^ Schneider et al suggested that different aspects of emotional behaviour were impaired in subtypes of schizophrenia, and it may be meaningful to compare emotional deficits in different subgroups of patients with schizophrenia.^\[[@ref21]\]^

In this study, we examined pleasure experience and emotion expression in patients with schizophrenia. In particular, we categorized patients with schizophrenia into those with prominent negative symptoms and those without using a set of well-recognized pre-defined criteria to examine the relationship between emotion impairments (both pleasure experience and expression) and negative symptoms. We hypothesized that patients with schizophrenia would exhibit impaired anticipatory pleasure experience and reduced emotion expression, but relatively intact consummatory pleasure experience. We further hypothesized that schizophrenia patients with prominent negative symptoms would exhibit more severe deficits in abstract pleasure experience than those without prominent negative symptoms.

2. Methods {#sec1-2}
==========

2.1. Participants {#sec2-1}
-----------------

One hundred and fifty in-patients with schizophrenia fulfilling DSM-IV criteria^\[[@ref22]\]^ were recruited from the Beijing Huilongguan Hospital and the Shanghai Mental Health Center. Exclusion criteria included a history of (1) substance abuse or other mental disorders; (2) electroconvulsive therapy in the past three months; (3) neurological disorder; (4) head injury with loss of consciousness for more than 30 minutes; and (5) other major organ disorders. All participants were assessed by qualified psychiatrists using structural interviews to ensure the absence of any Axis I DSM-IV psychiatric disorders. The average duration of illness of the participants was 5.80 years (SD=5.09 years, median=4.79 years, Quartile interval: 2.00 years-8.75 years) and the mean antipsychotic dosage in chlorpromazine equivalence was 299.83mg/day (SD=193.73mg/day, median=250.00mg/day, Quartile interval: 150mg/day-400mg/day). Participants' intelligence was estimated using a prorating method based on the Arithmetic, Similarities and Digit span subscales of the Chinese version of the Wechsler Adult Intelligence Scale-Revised.^\[[@ref23]\]^

We categorized the participants into those with and without prominent negative symptoms based on scores of the Positive and Negative Syndrome Scale^\[[@ref24]\]^ according to the following criteria that have been established in previous studies^\[[@ref25]\]^: (1) Baseline score \> 4 (moderate) on at least three, or \> 5 (moderately severe) on at least two negative PANSS subscale items^\[[@ref26],[@ref27]\]^; or (2) PANSS negative subscale score \> 3 on item 1 (blunted affect) and at least one third of the items had a score of \> 3 and a maximum of two items with a score \> 3 on the positive subscale.^\[[@ref28]\]^ Based on these criteria, a total of 17 patients were classified as having prominent negative symptoms, while 133 patients were classified as without prominent negative symptoms. There were no differences in the estimated intelligence quotient (IQ) (*t*(19)=1.37, *p*=0.19) and antipsychotic dosage (*t*(16)=0.58, *p*=0.57) between the two groups, but patients with prominent negative symptoms had a shorter duration of illness than patients without prominent negative symptoms (*t*(28)=2.67, *p*=0.01).

We also recruited 105 healthy individuals from the community who were matched with the patients by gender, years of education and age as controls. None of them had any lifetime or family history of psychosis, or a history of substance abuse or neurological disorders. The present study was approved by the Ethics Committees of the Institute of Psychology, the Beijing Huilongguan Hospital and the Shanghai Mental Health Center. Informed consent was obtained from all participants.

2.2. Measures {#sec2-2}
-------------

### 2.2.1. Positive and Negative Syndrome Scale (PANSS) {#sec3-1}

Positive and Negative Syndrome Scale (PANSS) measures the positive, negative and general syndrome in schizophrenia.^\[[@ref24]\]^ The interview-based scale contains 30 items, and each item is scored on a seven-point Likert scale, ranging from 1 ("absent") to 7 ("extreme"). The PANSS positive subscale includes seven items (e.g. delusions; conceptual disorganization); the negative subscale contains seven items (e.g. blunted affect; emotional withdrawal); and the general psychopathology subscale includes 16 items (e.g. somatic concern; anxiety). The positive, negative and general psychopathology subscales possess high internal consistency (Cronbach's alpha coefficients: 0.73, 0.78 and 0.79).

### 2.2.2. Temporal Experience of Pleasure Scale (TEPS) {#sec3-2}

The TEPS consists of 18 items, with a six-point Likert scale, ranging from "very false for me" to "very true for me".^\[[@ref29]\]^ It comprises 10 items for anticipatory pleasure and eight items for consummatory pleasure. The overall scale and subscales show good internal consistency (Cronbach's alphas: 0.79, 0.74, and 0.71 for the total score, the anticipatory subscale score and the consummatory subscale score, respectively). The Chinese version of the TEPS used in this study extended the two-factor structure into a four-factor model, consisting of 20 items.^\[[@ref11]\]^ The four-factor model includes abstract anticipatory pleasure, contextual anticipatory pleasure, abstract consummatory pleasure and contextual consummatory pleasure. The abstract items refer to stating something abstract or conceptual such as "Looking forward to a pleasurable experience is in itself pleasurable", while the contextual items refer to concrete and tangible events such like "When I hear about a new movie starring my favourite actor, I can't wait to see it". Good internal consistency of this Chinese version (Cronbach alphas ranging from 0.63 to 0.83) have been demonstrated in the Chinese setting.

### 2.2.3. Emotional Expressivity Scale (EES) {#sec3-3}

Emotional Expressivity Scale (EES) is a 17-item Likert self-reported questionnaire with a possible rating from 1 (never true) to 6 (always true).^\[[@ref30]\]^ It assesses individual differences in emotional expressivity and had high internal consistency and test-retest reliability. Chan et al reported a two-factor structure of the EES in the Chinese setting, namely the Expression Subscale (e.g. I can't hide the way I am feeling) and the Suppression Subscale (e.g. I keep my feelings to myself).^\[[@ref31]\]^ The Chinese version has been shown to have good internal consistency (Cronbach's alpha = 0.816 for the total score, 0.84 and 0.778 for the Expression and Suppression Subscale scores, respectively).

2.3. Data analysis {#sec2-3}
------------------

We used independent-samples *t* test to compare the TEPS and the EES scores of patients and healthy controls. One-way ANOVAs were conducted to assess group differences between patients with and without prominent negative symptoms and healthy individuals. Post-hoc analysis was conducted using the Least Square Differences (LSD) test.

3. Results {#sec1-3}
==========

3.1. Demographics {#sec2-4}
-----------------

[Table 1](#table001){ref-type="table"} shows the demographic information of the patients with schizophrenia and healthy controls. There were no significant differences in gender (χ2=0.76, *p*=0.38), years of education (*t*(253)=-1.38, *p*=0.17) and age (*t*(227)=0.35, *p*=0.73) between the two groups. However, patients with schizophrenia had significantly lower IQ estimates than healthy controls.

3.2. Comparison of TEPS and EES scores between schizophrenia patients and healthy controls {#sec2-5}
------------------------------------------------------------------------------------------

Patients with schizophrenia experienced less pleasure than healthy controls in the following domains: abstract anticipatory pleasure (*t*(243)=-3.86, *p*\<0.001, Cohen's *d*=0.49), abstract consummatory pleasure (*t*(250)=-2.58, *p*=0.010, Cohen's *d*=0.32), contextual consummatory pleasure (*t*(248)=-3.56, *p*=0.001, Cohen's *d*=0.45), overall consummatory pleasure (*t*(176)=-2.91, *p*=0.002, Cohen's *d*=0.31) and TEPS total (*t*(247)=-2.45, *p*=0.015 Cohen's *d*=0.38). There were no significant differences in expression of emotion between the two groups (see [Table 1](#table001){ref-type="table"}). In addition, in the multivariate analysis of gender and group (patient group, control group), the main effect of gender was significant, but the main effect of group and the interaction effect were not significant.

3.3. Difference in performance on the TEPS and the EES between patients with and without prominent negative symptoms and controls {#sec2-6}
---------------------------------------------------------------------------------------------------------------------------------

[Table 2](#table002){ref-type="table"} and [Figure 2](#fig002){ref-type="fig"} summarize the TEPS and EES scores between patients with and without prominent negative symptoms and healthy controls. The post-test of ANOVA showed that patients without prominent negative symptoms reported experiencing significantly less abstract anticipatory pleasure (*p*=0.001, Cohen's *d*=0.44), less abstract consummatory pleasure (*p*=0.017, Cohen's *d*=0.31), less contextual consummatory pleasure (*p*=0.005, Cohen's *d*=0.38), and had a lower total score on the TEPS consummatory pleasure factor (*p*=0.008, Cohen's *d*=0.35) than healthy individuals. Patients with prominent negative symptoms had lower scores than healthy controls in the following domains: abstract anticipatory pleasure (*p*\<0.001, Cohen's *d*=1.12), abstract consummatory pleasure (*p*=0.037, Cohen's *d*=0.57), contextual consummatory pleasure (*p*=0.008, Cohen's *d*=0.81), TEPS anticipatory pleasure (*p*=0.016, Cohen's *d*=0.73), and TEPS consummatory pleasure (*p*=0.005, Cohen's *d*=0.74). Compared with patients without prominent negative symptoms, patients with prominent negative symptoms had relatively lower scores on both the TEPS and the EES except for the EES total score. However, there was no significant difference between the three groups in overall EES scores.

4. Discussion {#sec1-4}
=============

4.1 Main findings {#sec2-7}
-----------------

Our findings showed that patients with schizophrenia experienced less abstract anticipatory pleasure but not contextual anticipatory pleasure than healthy controls. This is consistent with results from Li et al.'s study, which showed that both patients with first-episode and chronic schizophrenia had deficits in abstract but not contextual anticipatory pleasure.^\[[@ref12]\]^ Patients with schizophrenia had difficulties in responding to the abstract anticipatory pleasure items of the TEPS, suggesting that they may have difficulty in envisioning abstract events. Contrary to our hypothesis, schizophrenia patients also exhibited deficits in consummatory pleasure, both in the abstract and contextual domains. Although most studies showed that patients were impaired in anticipatory pleasure and relatively intact in consummatory pleasure, some studies have also reported similar findings with our present results that patients were impaired in both anticipatory and consummatory pleasure experience.^\[[@ref10],\ [@ref32],\ [@ref33]\]^ A meta-analysis found that patients may be abnormal in regions of the brain related with consummatory pleasure.^\[[@ref34]\]^ However, some researchers have reported that schizophrenia patients showed less severe deficits in pleasure experience in laboratory conditions when presented with evocative stimuli directly.^\[[@ref35],\ [@ref36]\]^ An explanation of the difference is that self-reported scales (e.g. TEPS) require more cognitive engagement. Since schizophrenia patients are often cognitively impaired, they may exhibit more severe impairment in pleasure experience when assessed using self-reported scales. Moreover, it has been suggested that self-reported measures such as the TEPS are designed to capture only hypothetical situations rather than "factual situations". ^\[[@ref37]\]^ The fact that the TEPS may not be able to measure consummatory pleasure in "hypothetical situations" may explain why our findings were different from the original anticipatory-consummatory differential deficit reported by Gard et al.^\[[@ref29]\]^

We found that schizophrenia patients with prominent negative symptoms showed more deficits in anticipatory pleasure, especially in abstract anticipatory pleasure. Some previous studies have reported similar findings in patients with prominent negative symptoms or individuals with negative schizotypal personality features.^\[[@ref16]\]^ Patients with prominent negative symptoms may be less motivated to anticipate pleasant events, resulting in reduced pleasure when anticipating those events. One explanation may be that patients with negative symptoms are impaired in memory,^\[[@ref38]\]^ which leads to difficulty in processing and integrating the pleasure they experience in the moment. Hence, they may be less motivated to seek pleasure in the future (anticipatory pleasure). In addition, a previous study has reported that un-medicated schizophrenia patients and patients taking conventional antipsychotics showed reduced activation in the ventral striatum in response to reward anticipation,^\[[@ref39]\]^ which was significantly associated with negative symptoms. It is interesting to note that our findings also demonstrated that the deficits in anticipatory pleasure were only present in the abstract facet but not in the contextual facet. This finding is consistent with Li's findings that abstract anticipatory pleasure is impaired across all stages of the schizophrenia spectrum.^\[[@ref12]\]^

Our findings in emotion expression were contrary to our expectation. There were no significant differences between schizophrenia patients and healthy controls in emotion expression, even after categorizing schizophrenia patients into those with and without prominent negative symptoms. There may be several possible explanations. First, it is commonly acknowledged that there is an "emotional paradox" in schizophrenia patients.^\[[@ref40]\]^ Emotional impairments may be mainly reflected in pleasure experience deficits instead of emotion expression in this clinical group. Secondly, previous studies have suggested that there may be gender differences in emotion expression, with women tending to be more emotionally expressive than men.^\[[@ref4],\ [@ref41],\ [@ref42]\]^ Since female patients made up nearly half of our sample, we speculated that the difference in emotion expression between genders might have attenuated the difference in the present study. However, such a speculation needs to be confirmed in future studies. Alternatively, people with schizophrenia may not be aware of their reduction in emotion expression even when these impairments in expression exist, which may not be captured using self-report scales such as the EES. Future studies should include objective measures to assess emotion expression in patients with schizophrenia.

4.2 Limitations {#sec2-8}
---------------

This study has several limitations. First, we only used self-reported scales to measure emotion experience and expression, which are relatively subjective and rely mainly on the participants' ability to recall particular experiences. Future studies should consider adopting additional objective measures such as computer-based tasks or measures to capture facial expression and speech production. Secondly, we recruited schizophrenia patients from two different areas: Beijing and Shanghai, and the assessments of clinical symptoms were completed by different clinicians. Although they were all experienced clinicians, there might have been inter-observer variation in the ratings. Thirdly, the sample of schizophrenia patients with prominent negative symptoms was small. Future studies should use a larger sample size of patients with prominent negative symptoms.

4.3 Implications {#sec2-9}
----------------

In this study, we explored the pleasure experience and emotional expression in patients with schizophrenia, especially in patients with and without prominent negative symptoms. The present findings suggest that patients with schizophrenia have deficits in pleasure experience, while their abilities to express emotion appear intact. Such deficits, in particular in abstract anticipatory pleasure, are more severe in patients with prominent negative symptoms. This could be helpful in investigating the relationship between negative symptoms and pleasure deficits in schizophrenia.
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###### 

Comparison of experiential pleasure and emotion expression between patients with schizophrenia and controls

                         SZ(n=150)        HC(n=105)       *T/~X~2*   *P*       Cohen's *d*
  ---------------------- ---------------- --------------- ---------- --------- -------------
  Gender(male: female)   86:65            54:51           0.76       0.38      
  Education (years)      12.67 (3.86)     13.24 (2.75)    -1.38      0.17      0.17
  Age (years)            29.31(9.16)      28.91 (8.83)    0.35       0.73      0.04
  IQ                     106.72 (17.61)   117.11(14.93)   -4.91      \<0.01    0.64
  ***TEPS***                                                                   
  Abstr_anti             17.57 (3.84)     19.27 (3.13)    -3.86      \<0.001   0.49
  Con_anti               15.98 (5.42)     15.82 (4.18)    0.27       0.798     0.03
  Abstr_con              25.11(6.34)      27.84 (10.39)   -2.58      0.010     0.32
  Con_con                14.01 (4.65)     15.84 (3.45)    -3.56      0.001     0.45
  TEPS_anti              33.77 (7.94)     35.09 (6.35)    -1.46      0.161     0.18
  TEPS_con               39.66 (8.81)     43.70 (12.03)   -2.91      \<0.002   0.38
  TEPS_total             75.07 (15.31)    79.93(15.62)    -2.45      0.015     0.31
  ***EES***                                                                    
  EES_exp                17.79 (5.26)     17.50 (4.46)    0.45       0.655     0.06
  EES_sup                33.13 (8.86)     33.24 (6.77)    -0.11      0.918     0.01
  EES_total              61.16 (10.89)    61.15 (9.56)    0.01       0.996     0.00

**For abbreviations, Abstr_anti=abstract anticipatory pleasure, Con_anti=contextual anticipatory pleasure, Abstr_con=abstract consummatory pleasure, Con_con=contextual consummatory pleasure, TEPS_anti=TEPS anticipatory pleasure, TEPS_con=TEPS consummatory pleasure, EES_exp=EES expression, EES_sup=EES suppression.**

###### 

Comparisons of experiential pleasure and emotion expression between patients with and without prominent negative symptoms, and controls.

  -----------------------------------------------------------------------------------------------------------------------------------------
               Non-NS (n=133)   NS (n=17)   HC (n=105)   *F*     *P*       Non-NS vs NS   Non-NS vs HC   NS vs HC                    
  ------------ ---------------- ----------- ------------ ------- --------- -------------- -------------- ---------- ------ --------- ------
  TEPS                                                                                                                               

  Abstr_anti   17.77\           15.76\      19.30\       10.01   \<0.001   0.028          0.57           0.001      0.44   \<0.001   1.12
               (3.86)           (3.19)      (3.12)                                                                                   

  Con_anti     16.16\           14.71\      15.80\       0.70    0.498                                                               
               (5.60)           (4.16)      (4.17)                                                                                   

  Abstr_con    25.28\           23.35\      27.89\       4.02    0.019     0.367          0.33           0.017      0.31   0.037     0.57
               (6.43)           (5.29)      (10.01)                                                                                  

  Con_con      14.20\           12.82\      15.78\       6.02    0.003     0.205          0.32           0.005      0.38   0.008     0.81
               (4.74)           (3.80)      (3.48)                                                                                   

  TEPS_anti    34.19\           30.47\      35.10\       3.00    0.052     0.049          0.51           0.344      0.13   0.016     0.73
               (8.07)           (6.38)      (6.32)                                                                                   

  TEPS_con     40.09\           36.18\      43.69\       5.86    0.003     0.139          0.49           0.008      0.35   0.005     0.74
               (8.07)           (8.01)      (11.97)                                                                                  

  TEPS_total   75.99\           67.88\      79.92\       5.17    0.006     0.042          0.57           0.053      0.25   0.003     0.85
               (15.47)          (12.76)     (15.54)                                                                                  

  EES                                                                                                                                

  EES_exp      17.92\           16.76\      17.51\       0.51    0.603                                                               
               (5.49)           (3.07)      (4.44)                                                                                   

  EES_sup      33.15\           32.82\      33.26\       0.02    0.977                                                               
               (7.91)           (7.91)      (6.74)                                                                                   

  EES_total    61.16\           61.24\      61.13\       0.00    0.999                                                               
               (11.27)          (8.11)      (9.52)                                                                                   
  -----------------------------------------------------------------------------------------------------------------------------------------

**For abbreviations, NS = patients with prominent negative symptoms. Non-NS= patients without prominent negative symptoms; HC = Healthy Controls**
